123 related articles for article (PubMed ID: 1673269)
21. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.
Tempero M; Takasaki H; Uchida E; Takiyama Y; Colcher D; Metzgar RS; Pour PM
Am J Surg Pathol; 1989; 13 Suppl 1():89-95. PubMed ID: 2699170
[TBL] [Abstract][Full Text] [Related]
24. Tumor markers in pancreatic cancer--current concepts.
Schmiegel W
Hepatogastroenterology; 1989 Dec; 36(6):446-9. PubMed ID: 2693300
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
26. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Int J Pancreatol; 1987; 2(5-6):349-60. PubMed ID: 3320227
[TBL] [Abstract][Full Text] [Related]
27. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
30. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer.
Satake K; Chung YS; Yokomatsu H; Nakata B; Tanaka H; Sawada T; Nishiwaki H; Umeyama K
Int J Pancreatol; 1990; 7(1-3):25-36. PubMed ID: 2081926
[TBL] [Abstract][Full Text] [Related]
31. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
[TBL] [Abstract][Full Text] [Related]
32. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
Pålsson B; Masson P; Andrén-Sandberg A
Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
34. Tumour markers in pancreatic cancer.
Haglund C; Kuusela P; Roberts PJ
Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
36. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
38. Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Basso D; Fabris C; Del Favero G; Panucci A; Plebani M; Angonese C; Leandro G; Dodi G; Burlina A; Naccarato R
Oncology; 1988; 45(1):24-9. PubMed ID: 3422390
[TBL] [Abstract][Full Text] [Related]
39. The monoclonal antibody-defined CAR-3 antigen is a serological marker associated with pancreatic carcinoma.
Prat M; Medico E; Piantino P; Bretti S; Rossini FP; Comoglio PM
Int J Biol Markers; 1988; 3(1):29-35. PubMed ID: 2977786
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic value of radioimmunological analysis of CA-19-9 in the blood serum in cancer of the pancreas].
Putseva NM; Chebotareva ED; Chernyĭ VA; Tashchiev RK
Klin Khir (1962); 1989; (11):15-7. PubMed ID: 2625847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
